Should Hypertonic Saline Be Considered for the Treatment of Intracranial Hypertension? A Review of Current Evidence and Clinical Practices

• Published in: Korean journal of neurotrauma 2024, 20(3), , pp.146-158
• Main Authors: Park, Moowan, Shim, Youngbo, Choo, Yoon-Hee, Kim, Hye Seon, Kim, Jungook, Ha, Eun Jin
• Format: Article
• Language: English
• Subjects: Review; 신경외과학
• ISSN: 2234-8999; 2288-2243
• DOI: 10.13004/kjnt.2024.20.e35

Intracranial hypertension (IH) is a critical neurological emergency that requires prompt intervention because failure to treat it properly can lead to severe outcomes, including secondary brain injury. Traditionally, mannitol (MNT) has been the cornerstone of hyperosmolar therapy. However, the use of hypertonic saline (HTS) has become increasingly important because of its unique advantages. Both HTS and MNT effectively reduce intracranial pressure by creating an osmotic gradient that draws fluid from brain tissue. However, unlike MNT, HTS does not induce diuresis or significantly lower blood pressure, making it more favorable for maintaining cerebral perfusion. Additionally, HTS does not cause rebound edema and carries a lower risk of renal injury than MNT. However, it is important to note that the use of HTS comes with potential risks, such as hypernatremia, hyperchloremia, and fluid overload. Due to its unique properties, HTS is a crucial agent in the management of IH, and understanding its appropriate use is essential to optimize patient outcomes.